Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $13.75

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have earned an average rating of “Hold” from the five ratings firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $13.75.

TBPH has been the subject of a number of research analyst reports. StockNews.com cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Leerink Partners cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $15.00 to $10.00 in a research note on Tuesday, August 6th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a research report on Monday, September 16th. Leerink Partnrs cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Finally, TD Cowen lowered their price target on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th.

Theravance Biopharma Stock Up 0.5 %

Shares of TBPH opened at $9.97 on Thursday. The stock’s fifty day simple moving average is $8.48 and its 200-day simple moving average is $8.70. The firm has a market capitalization of $490.22 million, a PE ratio of -9.87 and a beta of 0.25. Theravance Biopharma has a 12-month low of $7.44 and a 12-month high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The business had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. During the same quarter in the previous year, the firm posted ($0.17) EPS. Analysts anticipate that Theravance Biopharma will post -1.04 EPS for the current year.

Insiders Place Their Bets

In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now directly owns 322,743 shares of the company’s stock, valued at $2,904,687. The trade was a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new stake in shares of Theravance Biopharma during the third quarter worth $60,000. China Universal Asset Management Co. Ltd. grew its stake in Theravance Biopharma by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 3,696 shares during the period. Hsbc Holdings PLC bought a new stake in Theravance Biopharma in the second quarter worth approximately $108,000. Ballentine Partners LLC acquired a new stake in shares of Theravance Biopharma during the 3rd quarter worth approximately $104,000. Finally, XTX Topco Ltd acquired a new position in shares of Theravance Biopharma during the 2nd quarter valued at $129,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.